This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m 2 clofarabine for patients below and above 60 years. The most frequently reported grade 3-4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.
Clofarabine is a second-generation purine nucleoside analogue which has shown synergistic activity with cytarabine (Gandhi et al, 1993) . Single agent activity was promising, with a 42% complete remission (CR) rate in refractory acute myeloid leukaemia (AML)patients who were treated at a dose of 40 mg/m 2 /day for 5 days every 3-6 weeks (Kantarjian et al, 2003) . The Classic I trial evaluated the combination of clofarabine with cytarabine by randomly assigning 320 relapsed/refractory AML patients to receive either clofarabine 40 mg/m² or placebo followed by cytarabine 1 g/m² for five consecutive days. The CR rate was significantly better in the combination arm than in the cytarabine arm (35Á2% vs. 17Á8%, P < 0Á01), while the median overall survival (OS) was similar in the two arms (6Á6 vs. 6Á3 months) (Faderl et al, 2012) . Based on these data we and others hypothesized that the combination of clofarabine and cytarabine with an anthracycline might improve response rate and survival of newly diagnosed AML patients.
Patients and methods
Additional information on patients and methods is available in the supplementary data. Patients aged 18 years or older with newly diagnosed AML, as defined by the 2008 World Health Organization classification (Vardiman et al, 2009) , with high risk of induction failure and adequate organ function were eligible for entry into the trial. High risk of induction failure was defined as absence of translocations t (15;17), t(8;21) and inv(16)/t(16;16), absence of the fusion transcripts PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, and absence of NPM1 mutations. Patients with FLT3-mutated AML were excluded due to a competing trial with an FLT3 inhibitor (Stone et al, 2017) . Patients with a concomitant uncontrolled infection were not eligible. Written informed consent was obtained from all patients at study entry according to the Declaration of Helsinki. The study was approved by the local Ethics Review Committee and registered at https://www.clinicaltrialsregister.eu/(EudraCT 2010-021719-18).
The trial was a single-arm multi-centre phase I/II trial. All patients were planned to receive two cycles of standard induction therapy. Induction therapy was a combination of cytarabine 750 mg/m 2 intravenously over 2 h days 1-5, idarubicin 7Á5 mg/m 2 in patients <60 years or 6 mg/m 2 in patients ≥60 years, days 1 + 3 by a 5-to 10 min intravenous infusion with increasing doses of clofarabine (20-35 mg/m 2 intravenously over 1 h days 1-5) following a 3 + 3 design with extension cohorts (CIARA regimen). Cytarabine was administered four hours after the start of the clofarabine infusion to utilize the modulating effect of clofarabine on cytarabine metabolism (Gandhi et al, 1993) . In older patients a lower dosage of idarubicin was used and the dose escalation was stratified according to patient age (<60 years vs. Historical control cohorts were used to compare the results of the CIARA trial with previous trials. The AML-SHG 0295 (Heil et al, 2004) and AMLS-SHG 0199 (Heuser et al, 2006; Schlenk et al, 2008 ) trials served as a control for younger CIARA patients and the HD98B trial (Frohling et al, 2006) served as control for the older CIARA patients.
Results and discussion
Forty-two patients with newly diagnosed de novo (n = 32) or secondary AML (n = 10, 8 after myelodysplastic syndrome/ myeloproliferative neoplasm, 2 treatment-related) were recruited at six German university hospitals (see Table I for patient characteristics). All patients received induction 1, 27 (64%) received induction 2. Four (10%) patients died during induction courses 1 or 2. Nine dose limiting toxicities (DLTs) were noted in eight patients (Table S1 ) and the MTD was determined at 30 mg/m 2 clofarabine for both age cohorts (younger patients: 2 of 6 patients with DLT at 35 mg/m 2 , no DLT at 30 mg/m 2 (n = 9); older patients: 4 of 6 patients with DLT at 35 mg/m 2 in the extension phase, no DLT at 30 mg/m 2 (n = 3), Table S2 ). In the older patients, none of the first three patients developed a DLT with the 35 mg/m 2 dose for. Therefore, this dose level was expanded with six additional patients, of which 4 developed DLTs. This dose level could not be stopped earlier as all six patients had started treatment before the high DLT frequency became evident. The 30 mg/m 2 older patient group could not be expanded with additional patients as the recruitment limit had been reached. The most frequent non-haematological Short report 19 (45) 10 (42) 
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42 (100) 24 (100) 18 ( (Table S3 ). The most frequently reported grade 3-4 non-haematological all-causality adverse events were febrile neutropenia (55%), pneumonia (31%), sepsis (21%), increased liver enzymes (21%), decreased appetite (10%), diarrhoea (10%) and hypertension (10% , Table S3 ). In addition, grade 1/2 rash and mucosal inflammation were each found in 29% of patients. Fifty-one serious adverse events were reported, with sepsis (n = 7) and pneumonia (n = 4) being the most frequent. The median time to neutrophil recovery (≥0Á5 9 10 9 / l) and platelet recovery (≥50 9 10 9 /l) after induction 1 was 25 and 24 days, respectively. The median time to neutrophil and platelet recovery after induction 2 was 20 days each. CR was achieved in 50% of all patients (Table S4 ). The overall response rate (CR+CR with incomplete recovery [Cri]) was 69% in all patients. The early death rate at the end of induction was 10%. Patient characteristics and CR rates of younger and older patients from the CIARA trial and the respective control cohorts were similar (Tables S5,  S6 ). Sixteen patients (38%) proceeded to allogeneic haematopoietic cell transplantation (HCT) in first CR/CRi (14 younger, 2 older patients), and 8 (19%) patients received at least one course of high-dose cytarabine consolidation (4 younger, 4 older patients). Two younger and 3 older patients proceeded to allogeneic HCT at a later disease stage.
After a median follow-up of 2Á2 years the 1-and 2-year OS of all 42 patients was 64% and 56% (median OS not reached), the 1-and 2-year event-free survival (EFS) was 50% and 38% (median EFS 11Á4 months), and the 1-and 2-year relapse-free survival (RFS) of the 29 CR/CRi patients was 66% and 55% (median RFS not reached, Figures S1A-C) . CIR in the 29 CR/ CRi patients at 1 and 2 years was 26% and 34% ( Figure S1D ). The 2-year OS was higher for younger CIARA patients compared to a matched historical control of 182 younger AML patients [74% vs. 49%, hazard ratio (HR) 2Á66, 95% confidence interval (CI) 1Á17-6Á07, P = 0Á021, Fig 1A) . For the comparison with historical cohorts we considered patients in CR, but not CRi, as CRi had not been defined in these cohorts.
RFS of the 15 younger CIARA patients who achieved CR, was similar to RFS in the control cohort (HR 1Á98, 95% CI 0Á8-4Á94, P = 0Á13, Fig 1B) . The allogeneic HCT rate in first CR was higher in younger CIARA compared to younger control patients (58% vs. 29%, P = 0Á003, Table S5 ), which probably influenced OS.
We explored potential causes for the higher OS rate in younger patients, such as higher transplantation rate or deeper remission before allogeneic HCT. We found a trend towards improved OS in younger clofarabine-treated patients when OS was censored at allogeneic HCT (HR 2Á46, 95% CI 0Á9-6Á73, P = 0Á068, Figure S2 ). We also found an improved survival from the time of HCT in the clofarabine-treated patients (HR 4Á21, 95% CI 1Á03-17Á31, P = 0Á046 by Cox regression, P = 0Á10 by log-rank test, Figure S3 ). However, the relapse rate after HCT was identical for clofarabine-treated patients and historical controls [3 of 14 (21%) CIARA patients and 11 of 52 (21%) younger control patients], arguing against a better elimination of residual leukaemic stem cells by clofarabine compared to standard chemotherapy.
The allogeneic HCT rate in first CR was higher in the 18 older CIARA compared to the 187 older control patients (11% vs. 2%, Table S6 ). The 2-year OS was similar for older patients in the CIARA trial and older control patients (33% vs. 18%, HR 1Á17, 95% CI 0Á87-1Á56, P = 0Á31, Fig 1C) . The 2-year RFS of the 6 older patients from the CIARA trial, who achieved CR, was higher than in the control cohort (50% vs. 7%, HR 1Á8, 95% CI 1Á01-3Á23, P = 0Á036, Fig 1D) , but this result should be taken with caution due to small patient numbers.
Clofarabine has been previously used at the high dose of 30 mg/m 2 in combination with high-dose cytarabine (2 g/m 2 ) (Becker et al, 2015) , but not in combination with cytarabine and idarubicin. Renal toxicity has been a concern at higher doses of clofarabine , but was infrequently seen in our study. Jabbour et al (2017) used idarubicin 10 mg/ m 2 on days 1 to 3, cytarabine 1 g/m 2 on days 1 to 5 and clofarabine 15 mg/m 2 on days 1 to 5. This schedule resulted in similar 2-year EFS (44% vs. 38%) and 2-year OS (51% vs. Older (≥60 years) (n = 18) P value (younger versus older)
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56%) compared to our study. Lowenberg et al (2017) evaluated a cytarabine/anthracycline-based induction regimen in newly diagnosed AML patients aged 18 to 65, with and without clofarabine at 10 mg/m 2 on days 1-5. The study revealed no differences in OS and EFS between the control and clofarabine treatments in all patients, but showed a reduced relapse rate and increased probability of death in remission associated with clofarabine. Thus, the real value of clofarabine in intensive induction chemotherapy with cytarabine and an anthracycline is currently still uncertain. In summary, clofarabine can be safely administered at 30 mg/m 2 in combination with cytarabine and idarubicin in younger and older newly diagnosed AML patients. Allogeneic HCT in first complete remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical control patients.
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